AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 4025299 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A behavior pattern (A1-A2) overall
Number of subjects: 3110
Study 4025299 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A behavior pattern (A1-A2) in usual care (adjusted)
Number of subjects: 3110
Study 4025299 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A behavior pattern (A1-A2) in special intervention (adjusted)
Number of subjects: 3110
Study 4025299 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A behavior pattern (A1-A2) overall (adjusted)
Number of subjects: 3110
Study 4025299 — intervention group
Group type: EXPERIMENTAL
Intervention: Jenkins Activity Survey Type A score
Number of subjects: 3110
Study 30225903 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual regimen (low-fluence stamping mode at 5-6 J/cm2 followed by moving mode)
Number of subjects: 24
Study 30225903 — intervention group
Group type: COMPARATOR
Intervention: Conventional high-fluence stamp mode (14-15 J/cm2)
Number of subjects: 24
Study 30225903 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual regimen
Number of subjects: 24
Study 26777722 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic aerobic training (n = 17)
Number of subjects: 35
Study 26777722 — intervention group
Group type: COMPARATOR
Intervention: Dry-land aerobic training (n = 18)
Number of subjects: 35
Study 26777722 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic aerobic training
Number of subjects: 35
Study 26777722 — intervention group
Group type: COMPARATOR
Intervention: Dry-land aerobic training
Number of subjects: 35
Study 26777722 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study 24791618 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine
Number of subjects: 10
Study 24791618 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 10
Study 24791618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 22931394 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice pack applied for 10 minutes
Number of subjects: 114
Study 22931394 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice pack applied for 15 minutes
Number of subjects: 114
Study 22931394 — intervention group
Group type: COMPARATOR
Intervention: Ice pack applied for 20 minutes (historical control)
Number of subjects: 114
Study 20124953 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil with MPA-AUC less than 30 mg hr/L
Number of subjects: 549
Study 20124953 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil with MPA-AUC more than or equal to 30 mg hr/L
Number of subjects: 549
Study 20124953 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil with MPA-AUC less than 30 mg hr/L in tacrolimus-treated patients
Number of subjects: 549
Study 20124953 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil with MPA-AUC more than or equal to 30 mg hr/L in tacrolimus-treated patients
Number of subjects: 549
Study 20124953 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil in low-risk patients
Number of subjects: 549
Study 18612571 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice (brief intervention)
Number of subjects: 575
Study 18612571 — intervention group
Group type: COMPARATOR
Intervention: No advice (control)
Number of subjects: 575
Study 16796276 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg alendronate once weekly
Number of subjects: 335
Study 16796276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study 16796276 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate therapy
Number of subjects: 335
Study 16796276 — intervention group
Group type: COMPARATOR
Intervention: Age-matched control subjects
Number of subjects: 335
Study 12709133 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional relative colour histogram analysis technique using percent melanoma colour feature.
Number of subjects: 258
Study 10723850 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 67
Study 10723850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 8694320 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital pressure during interscalene block
Number of subjects: 20
Study 8694320 — intervention group
Group type: COMPARATOR
Intervention: No digital pressure during interscalene block
Number of subjects: 20
Study 1360032 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine doppler ultrasound examinations of the umbilical and uterine arteries during pregnancy (first at 19-22 weeks, then monthly for high risk or once at 32 weeks for low risk)
Number of subjects: 2475
Study 1360032 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard antenatal care with routine doppler examinations
Number of subjects: 2475
Study 1360032 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care without doppler ultrasonography
Number of subjects: 2475
Study 6146153 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 0
Study 31298705 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased mammographic density (MD) over time
Number of subjects: 43810
Study 31298705 — intervention group
Group type: COMPARATOR
Intervention: Stable mammographic density (MD)
Number of subjects: 43810
Study 31298705 — intervention group
Group type: COMPARATOR
Intervention: Increasing mammographic density (MD)
Number of subjects: 43810
Study 30791819 — intervention group
Group type: EXPERIMENTAL
Intervention: QuinteT Recruitment Intervention (QRI)
Number of subjects: 0
Study 28235424 — intervention group
Group type: EXPERIMENTAL
Intervention: BMMSC group
Number of subjects: 105
Study 28235424 — intervention group
Group type: EXPERIMENTAL
Intervention: BMMNC group
Number of subjects: 105
Study 28235424 — intervention group
Group type: COMPARATOR
Intervention: Control group (Bobath therapy)
Number of subjects: 105
Study 30641621 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine group (CM) - Astragalus Granule (AG)
Number of subjects: 150
Study 30641621 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group - Astragalus Granule (AG) and auricular point sticking
Number of subjects: 150
Study 30641621 — intervention group
Group type: COMPARATOR
Intervention: Western medicine group (WM) - Basic treatment with aerosol inhalation (Budesonide suspension and Terbutaline Sulphate Solution)
Number of subjects: 150
Study 23723319 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent HPV vaccine (HPV16/18), administered at 0, 1, and 6 months
Number of subjects: 68
Study 23723319 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent HPV vaccine (HPV16/18)
Number of subjects: 68
Study 23723319 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (not vaccinated)
Number of subjects: 68
Study 22019331 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5 μg, 2 doses per week for 48 weeks)
Number of subjects: 50
Study 22019331 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 50
Study 19436116 — intervention group
Group type: EXPERIMENTAL
Intervention: pilsicainide (150 mg/day)
Number of subjects: 59
Study 19436116 — intervention group
Group type: EXPERIMENTAL
Intervention: bepridil (200 mg/day)
Number of subjects: 59
Study 17263861 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal Voltarol
Number of subjects: 210
Study 17263861 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 210
Study 17263861 — intervention group
Group type: COMPARATOR
Intervention: No analgesia
Number of subjects: 210
Study 15194570 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (3 mg/kg)
Number of subjects: 12
Study 15194570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11529382 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten (9 mg/kg/day) for 10 days after initial ceftriaxone (75 mg/kg/day)
Number of subjects: 36
Study 11529382 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (75 mg/kg/day)
Number of subjects: 36
Study 11529382 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten (9 mg/kg/day)
Number of subjects: 36
Study 9779032 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin and ticlopidine
Number of subjects: 123
Study 9779032 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 123
Study 8142127 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sucralfate suspension (Group 2)
Number of subjects: 80
Study 8142127 — intervention group
Group type: COMPARATOR
Intervention: Antacid containing sodium alginate (Group 1)
Number of subjects: 80
Study 3203571 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of fructose
Number of subjects: 8
Study 3203571 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric amount of starch (control)
Number of subjects: 8
Study 30075198 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 282
Study 30075198 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic normothermia
Number of subjects: 282
Study 30075198 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe AKI
Number of subjects: 282
Study 27620342 — intervention group
Group type: EXPERIMENTAL
Intervention: EXER (exercise program)
Number of subjects: 66
Study 27620342 — intervention group
Group type: EXPERIMENTAL
Intervention: EXER + CBT (exercise program plus cognitive-behavioral therapy)
Number of subjects: 66
Study 27620342 — intervention group
Group type: COMPARATOR
Intervention: CONTROL (routine treatment)
Number of subjects: 66
Study 25780837 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural patients receiving surgical treatment for hip osteoarthritis
Number of subjects: 200
Study 25780837 — intervention group
Group type: COMPARATOR
Intervention: Urban patients receiving surgical treatment for hip osteoarthritis
Number of subjects: 200
Study 24326918 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubric exam preparation group
Number of subjects: 65
Study 24326918 — intervention group
Group type: COMPARATOR
Intervention: Nonrubric exam preparation group
Number of subjects: 65
Study 21353262 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption (beer, ∼26 g alcohol)
Number of subjects: 24
Study 21353262 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-free beer (control)
Number of subjects: 24
Study 19767761 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 G-needle
Number of subjects: 187
Study 19767761 — intervention group
Group type: COMPARATOR
Intervention: 18 G-needle
Number of subjects: 187
Study 16790200 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab bolus
Number of subjects: 137
Study 16790200 — intervention group
Group type: COMPARATOR
Intervention: Intravenous abciximab bolus
Number of subjects: 137
Study 15884481 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-frequency prenatal visits
Number of subjects: 0
Study 15884481 — intervention group
Group type: EXPERIMENTAL
Intervention: CenteringPregnancy (group prenatal care)
Number of subjects: 0
Study 11141361 — intervention group
Group type: EXPERIMENTAL
Intervention: Smears
Number of subjects: 139
Study 11141361 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultures
Number of subjects: 139
Study 9118185 — intervention group
Group type: EXPERIMENTAL
Intervention: F dentifrice (0.145% F as NaF) only
Number of subjects: 12
Study 9118185 — intervention group
Group type: EXPERIMENTAL
Intervention: F dentifrice + F lozenges (0.25 mg F x 6/day)
Number of subjects: 12
Study 9118185 — intervention group
Group type: EXPERIMENTAL
Intervention: F dentifrice + F chewing-gum (0.25 mg F x 6/day)
Number of subjects: 12
Study 9118185 — intervention group
Group type: COMPARATOR
Intervention: Control (F dentifrice only)
Number of subjects: 12
Study 8397836 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Precision Full Head soft toothbrush
Number of subjects: 72
Study 8397836 — intervention group
Group type: COMPARATOR
Intervention: Crest Complete soft toothbrush
Number of subjects: 72
Study 3538481 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine (20 mg thrice daily)
Number of subjects: 13
Study 3538481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31234691 — intervention group
Group type: EXPERIMENTAL
Intervention: C+C (cyclopentolate 1% + cyclopentolate 1%)
Number of subjects: 67
Study 31234691 — intervention group
Group type: EXPERIMENTAL
Intervention: C+T (cyclopentolate 1% + tropicamide 1%)
Number of subjects: 67
Study 31234691 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.5% (after C+C)
Number of subjects: 67
Study 31234691 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.5% (after C+T)
Number of subjects: 67
Study 31234691 — intervention group
Group type: EXPERIMENTAL
Intervention: C+C (dark pigmentation)
Number of subjects: 67
Study 31234691 — intervention group
Group type: EXPERIMENTAL
Intervention: C+T (dark pigmentation)
Number of subjects: 67
Study 31234691 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (dark pigmentation, crying)
Number of subjects: 67
Study 31234691 — intervention group
Group type: EXPERIMENTAL
Intervention: C+C (dark pigmentation, crying)
Number of subjects: 67
Study 31234691 — intervention group
Group type: EXPERIMENTAL
Intervention: C+T (dark pigmentation, crying)
Number of subjects: 67
Study 31234691 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (medium pigmentation, crying)
Number of subjects: 67
Study 31234691 — intervention group
Group type: EXPERIMENTAL
Intervention: C+C (medium pigmentation, crying)
Number of subjects: 67
Study 31234691 — intervention group
Group type: EXPERIMENTAL
Intervention: C+T (medium pigmentation, crying)
Number of subjects: 67
Study 29071764 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone
Number of subjects: 24
Study 25881320 — intervention group
Group type: EXPERIMENTAL
Intervention: Bravecto™ (fluralaner), 25 mg/kg body weight, single oral administration
Number of subjects: 16
Study 25881320 — intervention group
Group type: COMPARATOR
Intervention: Advocate® (imidacloprid/moxidectin), 10 mg imidacloprid/kg body weight and 2.5 mg moxidectin/kg body weight, topical administration on three occasions at 28-day intervals
Number of subjects: 16
Study 23741066 — intervention group
Group type: EXPERIMENTAL
Intervention: Quisinostat (JNJ-26481585) administered orally, once daily in three weekly cycles, with doses ranging from 2-12 mg for continuous dosing and 6-19 mg for intermittent dosing schedules.
Number of subjects: 92
Study 23741066 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent dosing schedules (four days on/three days off; every Monday, Wednesday, Friday; every Monday and Thursday)
Number of subjects: 92
Study 21162697 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol ER (100-250 mg bid)
Number of subjects: 588
Study 21162697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study 21162697 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label titration phase (Tapentadol ER)
Number of subjects: 588
Study 18971855 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.05% ciclosporin A (CsA) for 3 months after surgery
Number of subjects: 60
Study 18971855 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard topical therapy)
Number of subjects: 60
Study 17052283 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal health factors (hypertensive disorders)
Number of subjects: 1584
Study 17052283 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal health factors (antepartum haemorrhage)
Number of subjects: 1584
Study 17052283 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal health factors (higher haemoglobin levels)
Number of subjects: 1584
Study 17052283 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall perinatal mortality rate
Number of subjects: 1584
Study 17052283 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall stillbirth rate
Number of subjects: 1584
Study 12941721 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (5000 units subcutaneous injection once daily)
Number of subjects: 87
Study 12941721 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiological saline equivalent volume once daily)
Number of subjects: 87
Study 12941721 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 87
Study 12941721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 11019420 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMS) 60 mg
Number of subjects: 29
Study 11019420 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMS) added to selected antianginal drugs
Number of subjects: 29
Study 11019420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 11019420 — intervention group
Group type: COMPARATOR
Intervention: Propranolol, Verapamil, Isosorbide dinitrate, Nifedipine
Number of subjects: 29
Study 8618579 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized synthetic surfactant (13.5 mg of dipalmitoylphosphatidylcholine per milliliter) administered continuously for up to five days
Number of subjects: 725
Study 8618579 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.45 percent saline) administered continuously for up to five days
Number of subjects: 725
Study 8618579 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized synthetic surfactant
Number of subjects: 725
Study 8618579 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.45 percent saline)
Number of subjects: 725
Study 1570391 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 30
Study 1570391 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 30
Study 1570391 — intervention group
Group type: COMPARATOR
Intervention: No patches
Number of subjects: 30
Study 6089249 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.28 mg/kg)
Number of subjects: 0
Study 30609409 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn genomic sequencing (nGS)
Number of subjects: 159
Study 30016151 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (10 1-min cycling intervals at 95% peak workload, 3 times per week for 11 weeks)
Number of subjects: 16
Study 30016151 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Number of subjects: 16
Study 30016151 — intervention group
Group type: COMPARATOR
Intervention: Endurance Training (40-min cycling at 50% peak workload, 3 times per week for 11 weeks)
Number of subjects: 16
Study 30016151 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training modalities
Number of subjects: 16
Study 26749219 — intervention group
Group type: EXPERIMENTAL
Intervention: HYD 30 mg once daily
Number of subjects: 410
Study 26749219 — intervention group
Group type: EXPERIMENTAL
Intervention: HYD 20 to 120 mg
Number of subjects: 410
Study 26749219 — intervention group
Group type: EXPERIMENTAL
Intervention: HYD 120 mg once daily
Number of subjects: 410
Study 26749219 — intervention group
Group type: COMPARATOR
Intervention: HYD 30 mg
Number of subjects: 410
Study 25069991 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (o‐CEE), 0.45 mg/d, with 200 mg of oral progesterone for 12 days per month for 48 months
Number of subjects: 727
Study 25069991 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17β‐estradiol (t‐E2), 50 mcg/d, with 200 mg of oral progesterone for 12 days per month for 48 months
Number of subjects: 727
Study 25069991 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 48 months
Number of subjects: 727
Study 23179383 — intervention group
Group type: COMPARATOR
Intervention: D + 3 progesterone treatment
Number of subjects: 88
Study 23179383 — intervention group
Group type: EXPERIMENTAL
Intervention: D + 4 progesterone treatment
Number of subjects: 88
Study 23179383 — intervention group
Group type: EXPERIMENTAL
Intervention: Morula/blastocyst stage embryos
Number of subjects: 88
Study 23179383 — intervention group
Group type: COMPARATOR
Intervention: Cleavage stage embryos
Number of subjects: 88
Study 23179383 — intervention group
Group type: COMPARATOR
Intervention: Mixed stage transfers
Number of subjects: 88
Study 19732051 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5 mg
Number of subjects: 1058
Study 19732051 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg
Number of subjects: 1058
Study 19732051 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 1058
Study 19732051 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 1058
Study 19732051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1058
Study 19732051 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (2.5, 5, 10, 20 mg)
Number of subjects: 1058
Study 19732051 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 1058
Study 18044196 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy combined with other Cognitive‐Behavioral Therapy (CBT) components
Number of subjects: 16
Study 18044196 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 16563281 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Myocardial Infarction (AMI) group
Number of subjects: 50
Study 16563281 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable Angina (UA) group
Number of subjects: 50
Study 16563281 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable Angina (SA) group
Number of subjects: 50
Study 16563281 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 12392861 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm handheld computers for patient diaries
Number of subjects: 12
Study 12392861 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic reminders for protocol compliance
Number of subjects: 12
Study 12392861 — intervention group
Group type: COMPARATOR
Intervention: Traditional paper-based patient diaries
Number of subjects: 12
Study 11331450 — intervention group
Group type: EXPERIMENTAL
Intervention: GH/GLN
Number of subjects: 16
Study 11331450 — intervention group
Group type: COMPARATOR
Intervention: GLN
Number of subjects: 16
Study 9489976 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg mibefradil once daily for 2 weeks
Number of subjects: 95
Study 9489976 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg mibefradil once daily for 2 additional weeks
Number of subjects: 95
Study 9489976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95